Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; 7 of the 34 sources its claims cite were checked for support.
Abstract
We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B). Study A and study B were phase 1, randomized, crossover studies in healthy adults aged 18–65 years and 21–70 years, respectively. Participants received single (3 mg, study A) or multiple (16 mg, study B) oral doses of orforglipron under fasted and fed conditions. Blood samples were collected pre- and postdose to assess area under the concentration–time curve (AUC), maximum observed drug concentration ( C max ), time of C max ( t max ), and half-life ( t 1/2 ) associated with terminal rate constant. AUC and C max were analyzed using a linear mixed-effects model. Treatment differences were presented as ratios of geometric least squares means (GLSM). Treatment-emergent adverse events (TEAEs), adverse events of special interest, and serious adverse events were assessed. Study A included 12 participants (mean age 45.0 years; male 66.7%); study B included 34 participants (mean age 42.8 years; male 88.2%). GLSM AUC and C max were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively. In both studies, t 1/2 and median t max were comparable between fed and fasted states. The majority of TEAEs in both studies were gastrointestinal tract-related conditions. No serious adverse events or deaths were reported in either study. The observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity. ClinicalTrials.gov identifiers, NCT03929744 and NCT05110794.
Overview
CoChat Summary
TL;DR
In two phase 1 crossover studies in healthy adults, oral orforglipron exposure was modestly lower when given with food than fasted, with AUC and Cmax reductions of up to about 24%. The authors conclude these pharmacokinetic differences are unlikely to be clinically meaningful, and the safety profile was consistent with other GLP-1 receptor agonists.
Key findings
- Fed versus fasted geometric least squares mean AUC and Cmax were lower: in Study A (single 3 mg), AUC0–∞ was 23.7% lower and Cmax 23.2% lower; in Study B (multiple 16 mg), AUC0–24 was 17.6% lower and Cmax 20.9% lower.
- t1/2 and median tmax were comparable between fed and fasted states: Study A geometric mean t1/2 was 29.5 h fasted vs 27.9 h fed; Study B was 26.0 h fasted vs 24.6 h fed; median tmax was 8.0 h in both states in both studies, with no statistical difference (Study A p = 0.6875; Study B p = 0.0529).
- Most treatment-emergent adverse events were gastrointestinal; no serious adverse events or deaths occurred. Study A had TEAEs in 2/12 (16.7%) fasted and 0/12 fed; Study B had TEAEs in 18/28 (64.3%) fasted and 12/27 (44.4%) fed, with one participant (3.6%) discontinuing due to vomiting in the fasted condition.
- The authors state the observed PK differences due to prandial state are unlikely to contribute to clinically meaningful differences in efficacy, and orforglipron may offer convenience given the absence of prandial restrictions.
Methods
- Two phase 1, randomized, crossover studies in healthy adults: Study A (NCT03929744) tested a single 3 mg oral dose under fasted and fed conditions with a ~500 kcal meal (50% carbohydrate, 30% fat, 20% protein) and ≥5-day washout; Study B (NCT05110794) tested multiple 16 mg doses after titration under fasted and fed conditions with a ~800–1000 kcal high-fat meal (50% fat, 25–30% carbohydrate, 15–19% protein).
- PK parameters included AUC, Cmax, tmax, and t1/2; AUC and Cmax were log-transformed and analyzed with a linear mixed-effects model using treatment, period, and sequence as fixed effects and participant within sequence as random, with fed/fasted GLSM ratios and 90% CIs; tmax was analyzed non-parametrically using the Wilcoxon signed-rank test.
- Participants were overtly healthy men and women not of child-bearing potential: Study A included 12 participants aged 18–65 years with BMI 20–40 kg/m² and HbA1c <6.5%; Study B included 34 participants aged 21–70 years with BMI 18.5–35.0 kg/m² and specified hemoglobin thresholds.
Limitations
- The paper states both phase 1 studies included overtly healthy people, most of whom were male, and had small sample sizes; the results enabled phase 2 studies outside the clinical setting where dosing-condition compliance cannot be fully ensured, and ongoing phase 3 ACHIEVE and ATTAIN studies will further assess safety and efficacy regardless of prandial state.
- Evident from the text: Study B enrolled 34 participants but PK analyses included 28 fasted and 27 fed participants, with exclusions due to emesis affecting PK calculations, one discontinuation before treatment due to urticaria, and t1/2 not calculable for some participants because of insufficient quantifiable concentrations or poor adjusted R².
- Evident from the text: both studies were conducted at single centers, in healthy participants rather than patients with type 2 diabetes or obesity, and the food-effect assessments used specific standardized meals, so generalizability to other meals or patient populations is not established here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
5 Valid · 0 Not valid · 19 Not checked · 44 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Most currently approved GLP-1 RA treatments for patients with T2D or obesity are administered once weekly by subcutaneous injection [1].”
§ Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist > INTRODUCTION
What the sources say
- Partly supportedcites [1] Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023;161:170939. sourceExperimental — accuracy not yet measured
Our copy supports the route and the prominence of weekly dosing: the Introduction (p. 1) states GLP-1RAs 'are now available in most countries as once-daily and once-weekly injectable formulations' and that long-acting analogues act 'when administered by once-weekly subcutaneous injection', with Section 9 (p. 4) noting 'the need for injections' and Section 4 (p. 3) treating oral semaglutide as the exception. However, the source does not say that MOST approved GLP-1RA treatments are once-weekly: it describes the available products as both once-daily and once-weekly, and Table 1 (Section 2, p. 2, 'GLP-1 receptor agonists available in Europe and North America') lists exenatide BD, lixisenatide OD, liraglutide OD and oral semaglutide alongside the three QW products (Bydureon, Trulicity, Ozempic). The majority/'once weekly' quantification attributed to this source is therefore not stated by it. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The safety profile of orforglipron was consistent with previous reports and with the known safety profiles of other oral and injectable compounds in the GLP-1 RA pharmaceutical class [26,[28][29][30][31].”
§ Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist > DISCUSSION
What the sources say
- Not checked yetcites [26] Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472–83. source
- Supportedcites [28] Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634–41. source
The Discussion (p. ~1, opening paragraph of §4) states the orforglipron results are 'comparable to that reported for other early-phase oral and injectable compounds in the GLP-1RA pharmaceutical class,' and the Abstract concludes 'Orforglipron had a pharmacodynamic and safety profile similar to that of injectable GLP-1RAs.' The Discussion summary (§4) repeats that treatment produced 'an AE profile similar to that of other GLP-1RAs,' and §3.1 details the safety findings (mostly mild GI TEAEs, no SAEs, no hypoglycaemia, pulse-rate rises in line with Phase 1 studies of other GLP-1RAs) that underpin that comparison. The cited work is thus a 'previous report' of orforglipron's safety profile consistent with other oral and injectable GLP-1RAs, exactly as the citing sentence attributes. (LLM, conf=0.90)
- Not checked yetcites [29] Saxena AR, Gorman DN, Esquejo RM, et al. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021;27(6):1079–87. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GLSM AUC and C max were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively.”
- Also stated in: § Pharmacokinetics of Single and Multiple Oral Doses of Orforglipron in the Fasted and Fed States · plain
“Similarly, following oral administration of 16 mg orforglipron in study B, the GLSM AUC 0-24 and C max were 17.6% and 20.9% lower, respectively, in the fed state than the fasted state”
§ Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist > Abstract
plainstates a causen = 34- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Pharmacokinetics of Single and Multiple Oral Doses of Orforglipron in the Fasted and Fed States · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GLSM AUC and C max were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively.”
- Also stated in: § Pharmacokinetics of Single and Multiple Oral Doses of Orforglipron in the Fasted and Fed States · plain
“Following oral administration of 3 mg orforglipron in study A, the GLSM AUC 0-∞ and C max were 23.7% and 23.2% lower, respectively, in the fed state compared with the fasted state”
§ Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist > Abstract
plainstates a causen = 12- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Pharmacokinetics of Single and Multiple Oral Doses of Orforglipron in the Fasted and Fed States · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common TEAEs under the fasted condition were nausea, headache, and abdominal distension (each reported by four participants [14.3%])”
§ Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist > Safety and Tolerability of Orforglipron
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 68 claims and to verify the 27 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Food intake has minimal impact on systemic exposure, providing flexibility for administration in real-world settings [42].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [42]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Adherence to antihyperglycemic and antiobesity medications is associated with improved glycemic control and weight reduction, respectively [13, 14], whereas treatment non-adherence leads to increased risk of diabetes-related macrovascular and microvascular complications [15].”
Background2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · cited 1×
“Obesity treatment guidelines also recommend adjunct treatment with pharmacotherapies such as GLP-1 RAs when initial treatment through life-style interventions (nutrition, physical activity, and behavioral modifications) are unsuccessful [9–12].”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 2×
“Obesity treatment guidelines also recommend adjunct treatment with pharmacotherapies such as GLP-1 RAs when initial treatment through life-style interventions (nutrition, physical activity, and behavioral modifications) are unsuccessful [9–12].”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“In addition, these therapies reduce glucagon secretion and delay gastric emptying, facilitating weight reduction through a neuronally mediated satiety effect [1, 2].”
BackgroundSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · cited 1×
“…and abdominal distension (each reported by four participants [14.3%]), while the most common TEAEs under the fed condition were nausea (five participants [18.5%]), and abdominal distension and catheter site erythema (each reported by three participants [11.1%]; Table S1 in Supplementary material).”
BackgroundInfluentialMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Research works printed but not linked: 1
- ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2022;46(Suppl_1):S140–57.
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Self-citationKansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“These findings were subsequently corroborated in Phase 1b and Phase 2 studies enrolling participants with T2D, in whom baseline hepatic enzyme abnormalities are common due to metabolic liver disease [42,68].”
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Metadata
- Authors
- Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Ma, Xiaosu
- Venue
- Diabetes Therapy
- Published
- 2024-02-24
- Volume
- 15
- Issue
- 4
- Pages
- 819-832
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC10951152
- OpenAlex
- W4392138369
- Cited by
- 38
- References
- 34
- Citations by year
- 2026: 20 · 2025: 17 · 2024: 1
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- orforglipron, GLP-1 receptor agonists, food effect, prandial state, pharmacokinetics, drug safety and tolerability, gastrointestinal adverse effects, type 2 diabetes, obesity, oral administration, linear mixed models, area under the curve, half-life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. https://app.cochat.ai/papers/10.1007/s13300-024-01554-1
- The paper
- Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024). Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01554-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.